166 related articles for article (PubMed ID: 32358826)
1. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Zhang M; O'Keefe D; Iwamoto M; Sann K; Kien A; Hang V; Brucker C; Jolivet P; Ly S; Chhit D; Balkan S; Marquardt T; Le Paih M; Dousset JP
J Viral Hepat; 2020 Sep; 27(9):886-895. PubMed ID: 32358826
[TBL] [Abstract][Full Text] [Related]
2. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
[TBL] [Abstract][Full Text] [Related]
3. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
[TBL] [Abstract][Full Text] [Related]
5. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
6. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Luetkemeyer AF; McDonald C; Ramgopal M; Noviello S; Bhore R; Ackerman P
Clin Infect Dis; 2016 Jun; 62(12):1489-96. PubMed ID: 27025835
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
8. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
Elife; 2023 Jan; 12():. PubMed ID: 36622106
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis.
Indolfi G; Easterbrook P; Giometto S; Malik F; Chou R; Lucenteforte E
Liver Int; 2024 Mar; 44(3):663-681. PubMed ID: 38293756
[TBL] [Abstract][Full Text] [Related]
12. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis.
Zhuang L; Li J; Zhang Y; Ji S; Li Y; Zhao Y; Li B; Li W; Quan M; Duan Y; Zhao H; Cheng D; Wang X; Ou W; Xing H
Ann Hepatol; 2021; 23():100268. PubMed ID: 33059055
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
15. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Cordie A; Elsharkawy A; Abdel Alem S; Meshaal S; El Akel W; Abdellatif Z; Kamal W; Al Askalany M; Kamel S; Abdel Aziz H; Kandeel A; Esmat G
Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):232-240. PubMed ID: 31925434
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Nagaty A; Helmy SH; Abd El-Wahab EW
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
